Palatin Technologies INC

Palatin Technologies, Inc. announced the results of its annual meeting, with shareholders overwhelmingly approving director elections, auditor ratification, and amendments to the stock incentive plan.

Palatin Technologies, Inc. will voluntarily transfer its stock exchange listing from the NYSE American to the Nasdaq Capital Market effective May 29, 2026.

Palatin Technologies, Inc. announced its decision to hold annual non-binding advisory votes on executive compensation following stockholder approval at its 2025 Annual Meeting.

Palatin Technologies announced the closing of its $18.2 million public offering, including the full exercise of the over-allotment option, and regained NYSE American listing compliance.

Palatin Technologies announced a $15.8 million public offering and expects to resume trading on the NYSE American exchange, driven by a recent collaboration and capital raise.

Palatin Technologies announced a $6.5 million milestone payment from its collaboration with Boehringer Ingelheim for a retinal disease treatment.

Palatin Technologies reports Q3 2026 financial results, highlighting revenue growth from strategic licensing agreements and a strengthened cash position.

Palatin Technologies reports significant revenue growth from new collaborations and successful financing rounds, bolstering its cash position despite ongoing operating losses.

Palatin Technologies reported a significant shift to net income in Q1 2026, driven by a new collaboration and license agreement with Boehringer Ingelheim, while also regaining its NYSE American listing.

Palatin Technologies reports Q3 2025 results, highlighting ongoing losses, a delisting notice from NYSE American, and efforts to secure additional funding.

Palatin Technologies reports a net loss for Q2 2025 and expresses substantial doubt about its ability to continue as a going concern.

Palatin Technologies reported a net loss of $7.8 million for the quarter ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern.

Palatin Technologies reported a $17.3 million net loss for fiscal year 2025, faces delisting from NYSE American, but secured a significant collaboration with Boehringer Ingelheim and advanced multiple drug candidates.

Palatin Technologies reports a net loss of $29.7 million for fiscal year 2024 and expresses substantial doubt about its ability to continue as a going concern.

Carl Spana, President and CEO and a Director of Palatin Technologies Inc, reported multiple transactions in common stock on July 15, 2026.

Stephen T Wills, Executive VP and CFO/COO of Palatin Technologies Inc, reported multiple transactions in common stock on July 15, 2026.

Palatin Technologies Executive VP and CFO/COO Stephen T. Wills reported tax-related dispositions of common stock totaling 212 shares at $21.38 per share.

Palatin Technologies CEO Carl Spana reported the disposition of common stock shares to cover tax obligations related to vested equity grants.

Palatin Technologies' Executive VP and CFO/COO, Stephen T. Wills, sold 565 shares of common stock for estate planning purposes.

Palatin Technologies' Executive VP and CFO/COO, Stephen T. Wills, vested a significant portion of his restricted share units and performance-based stock options on December 9, 2025, following the achievement of defined performance objectives.

Palatin Technologies, Inc. has filed its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on July 28, 2026.

Palatin Technologies, Inc. is seeking shareholder approval for a reverse stock split to facilitate a potential Nasdaq uplisting, an increase in its equity incentive plan shares, and the issuance of common stock upon the exercise of recently issued warrants, following its delisting from NYSE American.

Palatin Technologies is holding its annual virtual stockholder meeting on June 27, 2024, to vote on director elections, auditor ratification, an amendment to the stock incentive plan, and executive compensation.

Palatin Technologies is conducting a public offering of common stock and warrants to raise capital, while simultaneously navigating delisting from NYSE American and ongoing litigation.

Palatin Technologies, Inc. filed an Amendment No. 1 to its S-1 registration statement, primarily to include an executed auditor consent from KPMG LLP, with no new securities being registered.

Palatin Technologies, Inc. announced a public offering of common stock and warrants to raise capital, while facing significant financial challenges and NYSE American delisting proceedings.

Palatin Technologies is seeking to raise capital through an offering of common stock, warrants, and pre-funded warrants, aiming to bolster working capital and fund development programs.

Palatin Technologies is seeking to raise capital through a public offering of common stock and warrants, aiming to bolster working capital and fund ongoing development programs.

Palatin Technologies files an amendment to its S-1 registration statement, enabling selling stockholders to offer up to 4,849,915 shares of common stock for resale.

Logos Global Management LP and associated entities have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Palatin Technologies Inc.

Sirenia Capital Management LP and Alex Silverstein report a combined 9.9% beneficial ownership in Palatin Technologies Inc., primarily through warrants.

AuGC BioFund LP, AuGC Partners LLC, and Evan Markegard have filed a Schedule 13G reporting a 5.3% beneficial ownership stake in Palatin Technologies Inc.

Driehaus Capital Management LLC has reported a 9.79% beneficial ownership stake in Palatin Technologies, Inc. common stock.

Janus Henderson Group plc and its affiliate have reported a 9.99% beneficial ownership stake in Palatin Technologies Inc. common stock.

Logos Global Management LP and its affiliates have disclosed a 9.9% beneficial ownership stake in Palatin Technologies Inc. following a recent share offering.